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ABSTRACT
The hepatitis C virus (HCV) NS5B is essential for
viral RNA replication and is therefore a prime target
for development of HCV replication inhibitors. Here,
we report the identification of a new class of HCV
NS5B inhibitors belonging to the coumestan family
of phytoestrogens. Based on the in vitro NS5B
RNA-dependent RNA polymerase (RdRp) inhibition
in the low micromolar range by wedelolactone,
a naturally occurring coumestan, we evaluated the
anti-NS5B activity of four synthetic coumestan
analogues bearing different patterns of substitu-
tions in their A and D rings, and observed a good
structure-activity correlation. Kinetic characteriza-
tion of coumestans revealed a noncompetitive
mode of inhibition with respect to nucleoside
triphosphate (rNTP) substrate and a mixed mode
of inhibition towards the nucleic acid template, with
a major competitive component. The modified order
of addition experiments with coumestans and
nucleic acid substrates affected the potencies of
the coumestan inhibitors. Coumestan interference
at the step of NS5B–RNA binary complex formation
was confirmed by cross-linking experiments.
Molecular docking of coumestans within the
allosteric site of NS5B yielded significant correlation
between their calculated binding energies and IC50
values. Coumestans thus add to the diversifying
pool of anti-NS5B agents and provide a novel
scaffold for structural refinement and development
of potent NS5B inhibitors.
INTRODUCTION
Hepatitis C virus (HCV), a major human pathogen and
causative agent of parenteral non-A non-B hepatitis, is
often associated with the development of malignant
chronic disease, including steatosis, liver cirrhosis and
hepatocellular carcinoma(1–3).Hepatitis CVirusinfection
is estimated to be four to ﬁve times more prevalent than
HIV-1, with over 200 million cases globally, of which  4.1
million infections exist in the United States alone (4,5).
There isnovaccine againstHCV atpresent,or any eﬀective
therapy broadly targeting all genotypes of HCV. Treat-
ment options against HCV include pegylated interferon
a (PEG-IFN-a) alone or in combination with ribavirin,
a broad spectrum antiviral agent (6–8). Sustained virolo-
gical response (SVR) rates for the combination therapy are
below 50% for genotype 1 and up to 80% for genotypes
2 and 3, and are associated with severe side eﬀects resulting
in limited patient compliance of these drugs (9–12).
Moreover, HCV undergoes rapid genetic evolution
during replication, resulting in a vast mix of variants,
thereby presenting additional challenge towards eradica-
tion of the virus in infected patients (13–15). Thus, there is
an urgent need to develop improved therapeutic options to
combat HCV infections.
HCV is an enveloped, positive-stranded RNA virus
with a  9.6kb genome which encodes a single large
polyprotein of 3010 amino acids. Host and viral proteases
process this polyprotein into four structural (Core, E1,
E2 and p7) and six nonstructural proteins (NS2, -3, -4A,
-4B, -5A and -5B) (16). Most eﬀorts in the development
of novel HCV antiviral agents have focused on two
viral targets: the NS3 serine protease that cleaves HCV
proteins from the polyprotein precursor and the NS5B
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unique component of the viral replication machinery (17).
HCV NS5B is a 66kDa phosphoprotein with predomi-
nant perinuclear localization. Puriﬁcation of full-length
NS5B has been challenging due to its hydrophobic
C-terminal membrane anchorage domain. Consequently,
recombinant NS5B with 21 to 55 amino acid C-terminal
truncations has been puriﬁed from Escherichia coli or
baculovirus-infected insect cells, thereby facilitating
its structure-function investigations (18–24). Similar to
other polymerases, crystal structures of NS5B have
revealed a classical ‘right hand’ shape, with the character-
istic ﬁngers, palm and thumb subdomains (25–27).
In vitro, NS5B nonspeciﬁcally utilizes a wide range of
homo- or heteropolymeric RNA templates in a primer-
dependent or independent (de novo synthesis) fashion
(18,20,22,24,28,29), and its activity is stimulated by GTP
under speciﬁed conditions (30). A number of recent
studies have contributed towards establishing some insight
into the mechanism of NS5B inhibition (31–35). This
provides a platform for developing new inhibitors belong-
ing either to the nucleoside analogue class (NI) that
function as rNTP substrate mimics and block the elonga-
tion of new viral RNA strands or the nonnucleoside class
of inhibitors (NNI), which inhibit the RdRp activity by an
alternative mechanism (36,37).
Coumestans belong to the ﬂavonoids category of phyto-
estrogens. Members of this family have been reported to
possess diverse pharmacological properties such as anti-
hemorrhagic, antiproteolytic and antiphospholipase activ-
ities (38). For a long time, traditional and herbal folk
medicines have relied on naturally occurring coumestans
from plants of the family Fabaceae against a variety of
ailments. Wedelolactone, the naturally occurring active
ingredient of herbal medicine derived from Eclipta
prostrata and Wedelia calendulacea, has been extensively
used in South American native medicine as snake anti-
venom (38). In traditional Chinese medicine, coumestans
are used to treat septic shock and in Indian Ayurvedic
medicine as a treatment for liver diseases, skin disorders
and viral infections (39). Coumestans have been shown to
reduce cancer risk (40), potentially due to their structural
similarity to phytoestrogens. A series of coumestan
derivatives were recently reported to inhibit the rat Na
+,
K
+-ATPase activity and to bind to the GABAA receptors
from the rat brain (41). In another study, wedelolactone
and six coumestan analogues were reported to possess
antihepatotoxic activity (42). More recently, wedelolac-
tone has been shown to inhibit the NF-kB-mediated gene
transcription in cells by blocking the phosphorylation and
degradation of IkBa (43).
To date, the eﬀect of coumestan class of compounds
on any RdRp family of enzymes including HCV NS5B
has not been investigated. In this study, we describe the
identiﬁcation and characterization of coumestans as a
novel class of anti-NS5B agents. Based on structure-
activity relationship (SAR) investigations on wedelolac-
tone and four synthetic coumestan derivatives and
computer modeling analysis to comprehend the SAR,
we propose that this class of compounds may provide a
new scaﬀold for developing potent anti-NS5B inhibitors.
MATERIALS AND METHODS
Materials
Reagents were purchased from the following sources:
nickel-nitrilotriacetic acid (Ni-NTA) agarose and NAP-10
columns were from GE Health care; radiolabeled [a-
32P]
rNTPs were purchased from Perkin Elmer; HPLC-grade
nucleoside triphosphate (NTP), RNase Out and glycogen
were from Roche; GF-B ﬁlters from Whatman; anti-His
antibody from Santa Cruz Biotechnology, Inc. and T4
polynucleotide kinase was obtained from Invitrogen.
All other chemicals were of the highest available molec-
ular biology grade and purchased from Fisher, Sigma or
Bio-Rad.
Synthesis of inhibitors
Wedelolactone (7-methoxy-5,11,12-trihydroxy-coumestan)
was purchased from EMD Chemicals Inc. and stored
as 50mM stock in 100% dimethylsulfoxide (DMSO).
The coumestan analogues LQB16, LQB34 (PCALC36),
LQB93 and LQB96 were synthesized as described pre-
viously (41,44). The purity of the synthesized coumestan
derivatives was >95% as assessed by
1H NMR and
13C NMR spectroscopy. These analogues were dissolved
in 100% DMSO as a 30mM stock. All compounds
were stored at  208C for not more than 2 weeks. Serial
dilutions of the inhibitors were made in DMSO immedi-
ately prior to the assay such that the ﬁnal concentration of
DMSO in all reactions was constant at 10%.
Purification of recombinant HCV NS5BC"21
Plasmid pThNS5BC21 was transformed in E. coli
DH5a and used for puriﬁcation of HCV NS5BC21
(45,46). This plasmid carries a hexahistidine tag (His-Tag)
at the N-terminus of NS5BNIH1b strain and lacks the
C-terminal 21 amino acid membrane-spanning domain.
Puriﬁcation was carried out following the method of Oh
etal.withminormodiﬁcations(45).Brieﬂy,theproteinwas
induced at 258C for 16h by addition of 0.2mM isopropyl-
b-D-thiogalactopyranoside (IPTG). The sonicated cell
lysates were clariﬁed by centrifugation at 30000g for
45min at 48C, chromatographed on a Ni-NTA column
(GE Health care) and washed in succession with
three diﬀerent buﬀers: NWB1 (50mM sodium phosphate
[pH 8.0], 10mM beta mercaptoethanol, 20mM imidazole,
2M NaCl, 2% Nonidet NP-40 and 10% glycerol), NWB2
(similar to buﬀer NWB1 except that it contains 1M NaCl
and 1% Nonidet NP-40), and NWB3 (similar to buﬀer
NWB1exceptthatitcontains100mMNaClandnoNP-40)
as described by Vo et al. (46). The bound protein was
eluted in 1mL fractions with NEB buﬀer (50mM sodium
phosphate [pH 8.0], 10mM beta mercaptoethanol,
100mM NaCl, 10% glycerol and 300mM imidazole) and
monitored by the Bradford colorimetric assay. The purity
of NS5BC21 was determined by Coomassie-stained
SDS-PAGE analysis. Fractions enriched in NS5BC21
(>95% purity) were pooled and dialysed against buﬀer A
(50mM Tris–HCl [pH 8.0], 1mM dithiothreitol (DTT),
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into aliquots and stored at  808C.
Purification of Klenowpolymerase and HIV-1 RT
Recombinant Klenow fragment of E. coli DNA polymer-
ase I was puriﬁed from an overproducing exonuclease
deﬁcient clone (pET-3a-K) expressed in E. coli BL-21
(DE-3) by ammonium sulfate fractionation and Biorex-70
column chromatography as described before (47). Enzyme
stocks were stored in aliquots at  208C in buﬀer I (50mM
Tris–HCl [pH 7.0], 1mM DTT, 100mM NaCl and 50%
glycerol).
Two recombinant plasmids, pET-28a-RT66 and
pET-28a-RT51 encoding p66 and p51 subunits of HIV-1
RT, respectively, with metal binding His-Tag sequences at
their N-terminal region were used for isolating wild-type
heterodimeric HIV-1 RT by Ni-NTA chromatography
as described before (48). The puriﬁed enzyme preparation
was found to be greater than 95% pure as judged by
SDS-PAGE and was stable at  208C for several months.
NS5BRdRp assay
The eﬀect of coumestan on the RdRp activity of NS5B
was evaluated by the standard primer-dependent elonga-
tion reactions employing synthetic homopolymeric
template-primers (TP) according to previously described
procedures with some modiﬁcation (24,47). Unless other-
wise speciﬁed, NS5B and RNA TP were incubated on ice
for 5min before the addition of NTPs. Enzymatic reaction
mixtures containing 20mM Tris–HCl (pH 7.0), 100mM
NaCl, 100mM sodium glutamate, 0.5mM DTT, 0.01%
BSA, 0.01% Tween-20, 5% glycerol, 20U/mL of RNase
Out, 0.5mM of poly rA/U12,2 5 mM UTP, 2–5mCi
[a-
32P]UTP, 300–500ng of NS5BC21 and 0.5mM
MnCl2 with or without inhibitors in a total volume of
25ml were incubated for 1h at 308C. The concentration of
DMSO in all reactions was maintained constant at 10%.
Reactions were terminated by the addition of ice-cold 5%
(v/v) trichloroacetic acid (TCA) containing 0.5mM pyro-
phosphate. The quenched reaction mixtures were incu-
bated at  208C for 1h to precipitate out denatured
polymeric RNA products, transferred to GF-B ﬁlters,
washed twice with 5% (v/v) TCA containing 0.5mM
pyrophosphate to remove unincorporated UTP, and
rinsed three times with water and once with ethanol
before vacuum drying (47). The amount of radioactive
UMP incorporated into RNA products was quantiﬁed on
a liquid scintillation counter (Packard). Activity of NS5B
in the absence of the inhibitor but containing an equiv-
alent amount of DMSO (control reaction) was set at
100% and that in the presence of the inhibitor was
quantiﬁed relative to this control. The concentration of
coumestans inhibiting 50% of NS5B RdRp activity (IC50)
were calculated from the inhibition curves as a function of
inhibitor concentration and values obtained represent
an average of at least two independent measurements.
N,N-disubstituted phenylalanine derivative # 14, a docu-
mented NS5B inhibitor (33), was included as an internal
standard in each set of experiments.
Reactions involving pre-incubation conditions were
designed as follows: in one set, coumestans were added
to the preformed NS5B-TP complex (45min at 48C) and
incubated further on ice for 5min. In a second set, NS5B-
compound complex (45min at 48C) was preformed prior
to the addition of the TP. In a third set, TP-coumestan
complex (45min at 48C) was preformed prior to the
addition of NS5B. In all cases, reactions were initiated by
the addition of a mixture of rNTPs, incubated at 308C for
1h and quenched by the addition of 5% (v/v) TCA
containing 0.5mM pyrophosphate. Product formation
was determined by GF-B ﬁlter binding assay as described
above. For each set, the eﬃcacy of the inhibitor under
modiﬁed order of reactions components was evaluated
(49,50).
HIV-1 RT and Klenow enzymatic assay
The speciﬁcity of the coumestans as inhibitors of HCV
NS5B was evaluated through HIV-1 RT and Klenow
polymerase counter screen employing standard methods
as described before (47,48) with slight modiﬁcation.
In brief, assays were carried out in a ﬁnal volume of
25ml in a reaction mixture containing 50mM Tris–HCl
[pH 7.8], 1mM DTT, 0.01% BSA, 50mM KCl, 200nM
poly rA/dT18,2 5 mM dTTP, 1mCi [a-
32P]dTTP, 10mM
MgCl2 and 10nM enzyme in the absence or presence of
the inhibitor. The concentration of DMSO in all reactions
was kept constant at 10%. Incubations were carried out at
378C for 20min, and reactions were terminated by the
addition of ice-cold TCA (5%) containing 0.5mM pyro-
phosphate. The reaction mixtures were ﬁltered through
GF-B ﬁlters, and radioactivity in the acid insoluble
fraction was determined by scintillation counting.
Gel-based incorporation assay
The incorporation of UMP on poly rA/U12 TP by
NS5BC21 at varying compound concentrations was
evaluated by gel analysis of products essentially as
described above for the HCV RdRp assay except that
the elongation time was reduced to 20min. Reactions were
stopped by the addition of 25mM EDTA and 0.5% SDS.
The RNA products recovered by phenol-chloroform
extraction and ethanol precipitation were dissolved in
formamide gel loading buﬀer (51). The samples were
heated at 908C for 5min and approximately one-ﬁfth of
the RNA products were resolved on a denaturing 6%
polyacrylamide gel containing 7M urea. The extent and
pattern of synthesis were visualized by phosphorimager
analysis and quantiﬁed using ImageQuant software
(Molecular Dynamics).
Cross-linking ofNS5B to TP
For cross-linking of NS5B to RNA, we engaged a
synthetic rA20/U12 TP. The U12-primer was 50-end-labeled
with [g-
32P] ATP using T4 polynucleotide kinase,
puriﬁed on a NAP-10 column as suggested by the
manufacturer, adjusted to the required speciﬁc radio-
activity with unlabeled primer and annealed with
equimolar concentrations of unlabeled rA20 template.
Cross-linking reactions as a function of inhibitor
1484 Nucleic Acids Research, 2008, Vol. 36, No. 5concentration were carried out as described earlier (47).
The reaction mixture, in a ﬁnal volume of 50ml contained
20mM Hepes (pH 7.0), 50mM NaCl, 0.5mM DTT,
0.01% BSA, 5% (v/v) glycerol, 20U/ml of RNase Out,
200nM of
32P-labeled U12/rA20 (15000c.p.m./pmol),
1.5mg of NS5BC21 and 0.5mM MnCl2. Reactions
were incubated on ice for 10min in the absence or
presence of the coumestans and were exposed to 254nm
UV irradiation at a dose of 300mJ/cm
2 (Spectronic
Corporation). The cross-linked species were resolved by
SDS-PAGE (8%). The dried gel was analysed on a
phosphorimager and the extent of cross-linking was
quantiﬁed using ImageQuant software.
Determination of theconstant(s) ofinhibition (Ki)
and mode of inhibition
The mode of inhibition by the coumestan derivatives
was evaluated essentially in two series of experiments as
described by McKercher et al. (52). The ﬁrst series
of experiments was performed by varying the TP (poly
rA/U12) and inhibitor concentrations. The concentration
of poly rA/U12 ranged from 0.2 to 2.5mM with a ﬁxed
concentration of UTP at 25mM. In the second set of
experiments, reaction velocities were determined at a ﬁxed
concentration of poly rA/U12 (0.25mM) and varying
concentrations of inhibitor and UTP (ranging from 2.5
to 80mM). In both series of experiments, the concentration
of inhibitors ranged 0.25–4 times their IC50 value. Assays
were carried out in the standard RdRp buﬀer described
above containing 300–500ng of NS5BC21 and 3–6mCi
[a-
32P] UTP. Aliquots were withdrawn at deﬁned times
and terminated by quenching with 5% TCA containing
0.5mM pyrophosphate. The extent of incorporation in
each set was determined by GF-B ﬁlter binding
assay. Kinetic results were then plotted according to the
methods of Dixon and Cornish-Bowden (53) in order to
determine the mode of inhibition and the Ki. Kinetic
experiments were performed at least twice and values are
averages of at least triplicate samples. Standard deviations
for all Ki were <10%.
Molecular modeling
All computations were carried out on a Dell Precision
470n workstation with the RHEL 4.0 operating system
using Glide 4.5 (Schrodinger LLC). For docking experi-
ments all the compounds were constructed using the
fragment dictionary of Maestro 8.0 and geometry
optimized using the Optimized Potentials for Liquid
Simulations-all atom (OPLS-AA) force ﬁeld (54) with
the steepest descent followed by truncated Newton conju-
gate gradient protocol as implemented in Macromodel
9.5. Water molecules of crystallization were removed
from the complex, and the protein was optimized for
docking using the protein preparation wizard provided
by Schrodinger LLC and the Impact program (First
Discovery v4.5). Partial atomic charges for compounds as
well as protein were assigned according to the OPLS-AA
force ﬁeld. The extra precision (XP) Glide docking
method as described elsewhere (55–58), was then applied
to dock the coumestans into the HCV NS5B NNI binding
sites for tetracyclic indole (PDB ID: 2DXS) (59),
N,N-disubstituted phenylalanine (PDB ID: 1NHU) (35)
and benzothiadiazine (PDB ID: 2FVC) (60) inhibitors.
Molecular dynamic (MD) simulations were carried out on
the NS5B-LQB34 complex (obtained by docking LQB34
at the NS5B NNI binding site for tetracyclic indole) using
the OPLS-AA force ﬁeld and a generalized Born/solvent-
accessible surface area (GB/SA) implicit water solvent
model with a dielectric constant of 78. The complex was
subjected to 1000ps MD simulations at 300K with an
integration step of 1fs. System coordinates were saved
every 2ps for further analysis. 3D structures and
trajectories were visually inspected using the Maestro
graphical interface. Root-mean-square (r.m.s) deviations
from the initial structures were calculated using super-
position option in Maestro. An average structure obtained
from the last 500ps of MD simulations was reﬁned by
means of 1000 steps of steepest descent followed by
conjugate gradient energy minimization. Conjugate gra-
dient energy minimizations were performed four times
using the positional restraints to all heavy atoms with
1000, 500, 100 and 0kJ/mol A ˚ 2 force constants in
sequence. The maximum number of cycles of minimiza-
tion was 5000 and the convergence criterion for the energy
gradient was 0.001kJ/mol A ˚ .
RESULTS
Expression and purification of recombinant HCV
NS5BC"21
Toinvestigate the inﬂuence of selected coumestan family of
compounds on the RdRp activity of NS5B, we employed
the N-terminal His-tagged HCV NS5B polymerase (geno-
type 1b), lacking the C-terminal 21-amino acid membrane-
spanning domain (NS5BC21). Deletion of the last 21
hydrophobic residues of NS5B has been reported to
enhance protein solubility (20), without compromising its
kinetic properties or its ability to perform both de novo and
primer-initiated RNA synthesis (51,61). We expressed the
recombinant NS5BC21 in bacteria (Figure 1, panel A),
and puriﬁed it by Ni-NTA aﬃnity chromatography.
In the ﬁnal step, the protein was batch eluted in 1ml
fractions with 300mM imidazole buﬀer. To ascertain the
purity and homogeneity of the eluted NS5BC21, aliquots
of eluted fractions were analysed by Coomassie blue
staining of the SDS-PAGE prior to pooling the fractions.
Eluates with the highest purity (>95%) were pooled,
dialysed and stored in aliquots at  808C. The puriﬁed
NS5BC21 corresponding to a single band of 64kDa
as visualized on a Coomassie blue-stained SDS-PAGE
(Figure 1, panel B), and analysed by western blot with anti-
His antibody (Figure 1, panel C) was used for all the
experiments described in this study. The RdRp activity and
integrity of the stored aliquots of NS5BC21 was found to
remain intact over a 2-year period.
Identification of coumestans asinhibitors
ofHCV NS5BRdRp activity
In a search for novel HCV NS5B inhibitors, we screened
the coumestan class of phytoestrogens for their inhibitory
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of an in vitro nucleotide incorporation assay on a homo-
polymeric poly rA/U12 TP by a functionally active
recombinant NS5BC21 enzyme. This culminated in the
identiﬁcation of wedelolactone, a naturally occurring
coumestan with a prototype coumestan scaﬀold (42), as
an inhibitor of HCV NS5B with an IC50 of 36.1mM
(Table 1). A positive control consisted of NS5B in
the absence of compound but containing equivalent
amount of DMSO (10%). N,N-disubstituted phenylala-
nine derivative # 14, included as an internal reference
standard in this investigation yielded an IC50 value of
0.3mM versus the reported IC50=0.7mM under our
experimental condition. This variance in IC50 value may
be attributed to the full-length recombinant NS5B
expressed from baculovirus-infected Sf9 insect cells and
a Flash-Plate scintillation proximity assay employed by
Chan et al. (33). The speciﬁcity of wedelolactone as
inhibitor of HCV NS5B polymerase was conﬁrmed by
HIV-1 RT (IC50>250mM) and Klenow polymerase
(IC50>700mM) counter screen.
Based on this preliminary investigation, we carried
out SAR analysis and biological characterization of
wedelolactone and four synthetic coumestan derivatives
bearing diﬀerent patterns of substitution on their
rings A and D (Table 1). All the ﬁve coumestans tested
inhibited the RdRp activity of NS5B, but with signiﬁcant
diﬀerences in their potency, with IC50 values that diﬀered
by up to more than one order of magnitude (Table 1).
Of these, LQB34 and wedelolactone, bearing catechol
group in their D-ring were found to be the most potent,
inhibiting NS5B activity with IC50 values of 18.5mM
and 36.1mM, respectively. This result suggests that change
in the positions of the hydroxyl and methoxy groups in the
A-ring of these coumestans did not substantially aﬀect
their anti-NS5B activity. Similarly, LQB96 bearing a less
polar cyclic methylenedioxy group in the D-ring and a
diﬀerent pattern of oxygenation at the A-ring exhibited a
slight decrease in its potency (2–3.5-fold) when compared
to wedelolactone and LQB34. LQB16, on the other hand,
carrying methylation of the phenol group in D-ring,
in addition to inversion in the position of the hydroxyl
and methoxy groups in A-ring as compared to LQB34,
was the least potent of the ﬁve coumestans with a near
20-fold increase in its IC50 value. Interestingly, this
dramatically decreased potency was improved by nearly
two-fold with LQB93, bearing identical D-ring to LQB16,
but carrying only the hydroxyl group in its A-ring.
Together, these data suggest that the presence of the
hydroxyl substituent in A-ring along with the catechol
group in the D-ring may be important for the anti-NS5B
eﬃcacy of the coumestans.
Gel-based incorporation assay
To determine the eﬀect of the coumestan compounds on
NS5BC21-mediated incorporation of rNTP substrates
into a growing RNA strand, we carried out gel-based
analyses of the reaction products. These assays are useful
in analysing the nature and pattern of the product synthe-
sized by polymerases family of enzymes and have been
reported by several groups in context of NS5B-inhibition
mechanism on a variety of TP (34,49,52). In our studies,
we employed the poly rA/U12 TP, and monitored
incorporation of radiolabeled [a-
32P] UTP substrate by
NS5BC21 in the presence of increasing concentrations
of the coumestans. The products were resolved on a 6%
denaturing urea gel and visualized by phosphorimaging.
As seen in Figure 2, reactions reconstituted with increas-
ing amounts of wedelolactone or LQB34 inhibited full-
length product formation as a function of inhibitor
concentration (Figure 2, lanes 2–5). The reduction in
product formation was higher in case of LQB34 compared
to wedelolactone at similar concentrations of the inhibitor
and is in agreement with their IC50 values. The reactions
containing inhibitors did not appear to produce shorter
products as a result of abortive initiation or premature
termination. As expected, no detectable extension product
was visible at the highest concentration of wedelolactone
(Figure 2, lane 5).
Mode ofinhibition
In order to gain insight into the mechanism of NS5B
inhibition by the three most potent coumestans,
we conducted two diﬀerent series of kinetic analyses of
enzyme inhibition. In the ﬁrst series, reaction velocities
were determined under conditions of varying concentra-
tions of TP and inhibitor in the presence of a constant
amount of UTP (Figure 3). In the second series, the
concentrations of UTP and inhibitor were varied in the
presence of a constant amount of TP (Figure 4). The data
obtained were analysed by Dixon and Cornish-Bowden
plots to determine the mode of inhibition and evaluate
the Ki values. It is clear from Figure 3 that the three
coumestan compounds displayed a mixed mode of
inhibition towards the TP, with a signiﬁcant competitive
Figure 1. Puriﬁcations of recombinant NS5B. Recombinant
NS5BC21 with N-terminal 6X Histidine-epitope tag was puriﬁed
from lysates of E. coli DH5a harboring the NS5BC21 expression
plasmid pThNS5BC21. The cells grown at 258C were induced with
IPTG (200mM). An aliquot of the induced culture was analysed by
SDS-PAGE and visualized by Coomassie blue staining. Panel A depicts
the induction proﬁle of NS5BC21 (indicated by asterisk). Clariﬁed
lysates of the induced culture were puriﬁed by nickel aﬃnity column
chromatography, eluted with 300mM imidazole containing NEB buﬀer
and dialysed overnight against buﬀer A (50mM Tris–HCl [pH 8.0],
1mM DTT, 100mM NaCl, 5mM MgC12 and 50% glycerol). The
puriﬁed protein corresponding to a single band of 64kDa is shown in
panel B. Panel C shows the immunoblot of puriﬁed NS5BC21
employing anti-His probe H-3 antibody (Santa Cruz Biotechnology).
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and a minor uncompetitive component (intercept extra-
polated from the Cornish-Bowden plot below the x-axis)
which corresponded to Ki competitive values of 11.2, 4.5
and 42.6mM and Ki uncompetitive values of 43, 37.5
and 342.3mM for wedelolactone, LQB34 and LQB96,
respectively. In contrast, the mode of inhibition by all
three coumestans emerged to be noncompetitive with
respect to UTP as seen in Figure 4, with distinct location
of the intercept on the x-axis in both the Dixon and the
Cornish-Bowden plots. The kinetic constants determined
from these plots corresponded to Ki values of 8.4, 4.2 and
42mM for wedelolactone, LQB34 and LQB96, respec-
tively. In all cases, the Ki constants correlated with the
IC50 values of the respective coumestans.
Modified order of addition influences potency ofcoumestans
Given the mixed mechanistic mode towards the RNA
template, we employed the modiﬁed order of reagent
addition experiments to identify the mechanistic step at
which this inhibition may be mediated. NS5B was pre-
incubated with either inhibitor or RNA before adding
the remaining components to initiate RNA synthesis. To
exclude the possibility that inhibition may be mediated as
a consequence of direct inhibitor binding to the RNA and
precluding it from the RdRp reaction, we set up another
series of reactions wherein the inhibitor was pre-incubated
with the RNA prior to the addition of the other
components. As seen in Figure 5, both wedelolactone
and LQB34 exhibited a downward shift in their IC50
Table 1. Structure–activity relationship of the Coumestan analogues
Compounds Structure NS5B inhibition
(IC50mM)
Log P Gscore
a Gscore
b
Wedelolactone
O
O
O
OH
OH
H3CO
OH
A
D
36.1 0.87  7.34  6.71
LQB16
H3CO O
O
O
OCH3
OH
A
D
HO
311 1.70  4.61  4.72
LQB34
H3CO
O
O
O
OH
OH
HO
A
D
18.5 0.82  7.53  6.91
LQB93
OCH3
O
O
O
OH
HO
A
D
174 1.52  6.63  6.32
LQB96
O
O
O HO
A
D
HO
O
O
63.8 0.98  6.91  6.28
The concentration of DMSO in all reactions was kept constant at 10%. The IC50 values of the coumestan analogues were determined from
dose–response curves using 8–12 concentrations for each compound in duplicate. Curves were ﬁtted to data points and IC50 values were interpolated
from the resulting curves using SigmaPlot 8.0 software. The values represent an average from at least two independent experiments.
N,N-disubstituted phenylalanine derivative 14 (IC50=0.3mM) was included as an internal reference standard. The predicted hydrophobicity of
the coumestans was determined from their log P values employing QikProp 3.0 program (Schrodinger software package). Gscore
a and Gscore
b values
were determined by docking of coumestans into NS5B NNI binding site for tetracyclic indole (PDB ID: 2DXS) and N,N-disubstituted phenylalanine
(PDB ID: 1NHU), respectively. A more negative Gscore indicates a better ﬁt at the binding site.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1487values upon pre-incubation with NS5B. Moreover, under
these conditions, complete inhibition was gradually
reached at higher inhibitor concentrations. Further,
separation of wedelolactone from the NS5B-inhibitor
pre-incubation complex on a Sephadex G25 column also
decreased the RdRp activity of NS5B (data not shown),
suggesting the direct binding of the inhibitor to NS5B.
Conversely, NS5B-RNA pre-incubation prior to the
addition of the inhibitor resulted in an upward shift of
the IC50 values. This increase was approximately four-fold
in case of LQB34 (from 18.5 to 70mM) against a modest
near two-fold increase seen with wedelolactone (36 to
80mM). In this scenario, the inhibition curves for LQB34
and wedelolactone depicted an altered trend since a
signiﬁcant fraction of NS5B activity was not inhibited
even at very high coumestan concentrations, this eﬀect
being more pronounced with LQB34. In addition, the
observation that the IC50 values did not change upon
pre-incubation of coumestans with the RNA suggests that
the inhibitor did not bind the RNA. Cumulatively, the
pre-incubation data is consistent with the kinetic experi-
ments and mode of inhibition and suggests that the
coumestans bind to NS5B directly and exert their inhi-
bitory eﬀect by interfering with an early step in the RdRp
reaction such as productive RNA binding to the enzyme.
RNA competes withcoumestan forNS5B binding
Similar to other polymerases, NS5B requires multiple sub-
strates, including a TP or a template-initiation nucleotide
complex in a sequential fashion, in which the ﬁrst
step is formation of the binary complex involving
binding of NS5B to the TP (62). We have earlier
demonstrated the formation of this binary complex by
polymerase-TP cross-linking experiments for the Klenow
fragment of E. coli DNA polymerase I (47), MuLV-RT
(63) and HIV-1 RT (48). The observation that pre-
incubation of NS5B-RNA protected the enzyme from
being inhibited by the coumestans, prompted us to
ascertain whether the coumestans adversely aﬀect
the binding of the TP to NS5B. A direct photochemical
cross-linking of 50-
32P-labeled U12/rA20 to NS5B was
performed by UV irradiation of the NS5B-TP complexes
in the presence of increasing amounts of coumestans
under standard RdRp assay conditions. The extent of
NS5B-TP covalent complex formed as a function of
inhibitor concentration was analysed by SDS-PAGE.
Results shown in Figure 6 indicate a reduction in the
E-TP binary complex formation in the presence of
the inhibitor. This reduction directly correlated with the
inhibitor concentration (Figure 6, lanes 2–9) and is in
agreement with the competitive mode of TP binding
as well as the protective eﬀect of RNA TP against
coumestan-mediated inhibition of NS5B. Further, the
reduction of NS5B-RNA binary complex species was
higher in case of LQB34 compared to wedelolactone and
correlated well withtheir respective IC50 values.The binary
complex formation data substantiates our hypothesis that
inhibition may be mediated at the RNA binding step
among others.
Hydrophobicity of coumestans
Hydrophobicity assessment is a valuable index utilized
during drug development since it serves as an excellent
predictor of drug absorption, bioavailability and drug-
receptor interactions. In order to examine the relationship
Figure 2. Eﬀect of coumestan derivatives on the RNA polymerase
activity of NS5B. The RdRp activity of NS5BC21 at increasing
concentrations of the indicated compounds was determined in a
standard RdRp assay containing poly rA/U12 as the TP and Mn
2+
as the divalent cation at 308C for 20min. The RNA product
synthesized was resolved on a 6% denaturing urea gel and visualized
by phosphorimaging. Lane 1 in each set represents the control reaction
carried out in the absence of the coumestan compound. Panel A: lanes
2–5 represent wedelolactone concentrations of 10, 25, 50 and 100mM.
Panel B: lanes 2–5 indicate LQB34 concentrations of 1, 5, 10, 25 and
50 mM, respectively. The position of the U12-primer is indicated by an
arrow to the left of the gel.
1488 Nucleic Acids Research, 2008, Vol. 36, No. 5Figure 3. Ki determination of coumestan compounds and mode of inhibition with regard to template/primer substrate. Reaction velocities were
measured at varying template/primer concentrations (0.2, 0.5, 0.7, 1.0, 1.5 and 2.3mM plotted as closed circles, open circles, closed triangles, open
triangles, closed squares and open squares, respectively) with ﬁxed concentration of UTP (25mM). Data were analysed by the Dixon and Cornish-
Bowden plots of the reciprocal velocity at indicated concentrations of the individual coumestan derivatives. All three coumestan derivatives displayed
a mixed mode of inhibition towards template/primer with a major competitive component (intercept on the Dixon plot above the x-axis) and a minor
uncompetitive component (intercept extrapolated from the Cornish-Bowden plot below the x-axis). The kinetic parameters corresponded to Ki
competitive values of 11.2, 4.5 and 42.6mM and Ki uncompetitive values of 43, 37.5 and 342.3mM for wedelolactone, LQB34 and LQB96,
respectively.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1489Figure 4. Evaluation of inhibition kinetic parameters of coumestan compounds with regard to UTP substrate. Reaction velocities were measured at
increasing concentrations of UTP substrate (2.5–80mM) on poly rA-U12 template/primer (0.25mM) in the absence or presence of increasing
concentrations (5–140mM) of the indicated inhibitor. Panels A, B and C depict the Dixon and Cornish-Bowden plots for wedelolactone, LQB34 and
LQB96, respectively. Both plots display similar intercept proﬁles on the x-axis indicating a noncompetitive mode of inhibition with regard to UTP.
The Ki values corresponded to 8.4, 4.2 and 42mM for wedelolactone, LQB34 and LQB96, respectively.
1490 Nucleic Acids Research, 2008, Vol. 36, No. 5between the coumestan-mediated inhibition of NS5B and
the chemical properties of this group of compounds, we
assessed the relationship between the calculated logP and
IC50 values. The logP value represents the partition
coeﬃcient, which is a measure of diﬀerential solubility of
a compound in octanol/water mixture. The logP values of
the coumestan compounds were calculated using QikProp
3.0 program available in Schrodinger software package
(Table 1) and plotted against their corresponding IC50
values (Figure 7). The derived logP values were least for
LQB34 and wedelolactone and highest for LQB16. A plot
of logP versus IC50 values of coumestans shows an inverse
correlation between hydrophobicity and inhibitory
potency of this class of compounds (Figure 7; P<0.02,
Spearman test). This observation may be predictive of a
trend for less hydrophobic coumestans to be better
inhibitors of NS5B and may assist in eﬀorts to design
better coumestan-based inhibitors.
Binding mode ofthe most potentcoumestan (LQB34)
To further understand SAR and investigate the potential
binding mode of the coumestan derivatives to HCV NS5B,
we performed molecular modeling studies employing
Glide docking software. To rule out any bias, each
of the three reported HCV NS5B NNI binding site
represented by tetracyclic indole (59), N,N-disubstituted
phenylalanine (35) and benzothiadiazine (60) inhibitors
was examined for coumestan binding. As a preliminary
step, we validated the accuracy of our docking approach
Figure 5. NS5B inhibition by wedelolactone (A) and LQB34 (B).
Dependence of inhibition curves on NS5B-RNA (TP+E), NS5B-
Inhibitor (E+I) and RNA-Inhibitor (TP+I) complex formation was
examined by pre-incubating the indicated components for 30min at 48C
followed by evaluation of the NS5B RdRp activity as described in
the text. UMP incorporation into product was expressed as percent of
control (no inhibitor) and plotted against increasing concentrations
of the indicated coumestan compounds.
Figure 7. Correlation between hydrophobicity and potency of coume-
stans. The predicted hydrophobicity of the coumestans was determined
from their logP values employing QikProp 3.0 program (Schrodinger
software package) and plotted against their IC50 values to establish
a correlation between the potency and hydrophobicity of the
coumestans (P<0.02, Spearman test).
Figure 6. Coumestans inhibit NS5B-RNA binary complex formation.
Binding of NS5B to RNA as a function of individual coumestan
derivative was evaluated by UV-mediated cross-linking. NS5BC21
(1.5mg) was incubated with 30 nM [50-
32P] labeled rA20/U12 template/
primer (200K Cerenkov c.p.m.) in a standard irradiation mixture in the
absence or presence of increasing concentrations of the indicated
coumestan compound and exposed to UV radiation. The cross-linked
species were resolved by SDS-PAGE and visualized on a phosphor-
imager. The extent of NS5B-RNA cross-linked species formed was
quantiﬁed using ImageQuant software (Molecular Dynamics). Lane 1
in each set represents the control reaction carried out in the absence of
the inhibitor. Lanes 2–9 represent indicated compounds at concentra-
tions of 1, 5, 10, 15, 30, 50, 100 and 200 mM, respectively.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1491by determining how closely ‘the lowest energy pose
(binding conformation)’ predicted by the object scoring
function, Glidescore (Gscore) in our case, resembles the
experimental binding mode as determined by X-ray
crystallography. Towards this end, we removed the
aforementioned crystallographic bound inhibitors from
their binding sites and then re-docked them into their
respective binding site on HCV NS5B polymerase. We
found a good agreement between the localization of the
inhibitor upon docking and from the crystal structure
as is evident from the 0.827, 0.748 and 0.297A ˚ root
mean square (rms) deviations for tetracyclic indole,
N,N-disubstituted phenylalanine and benzothiadiazine
inhibitors, respectively. This conﬁrms the reliability
of the Glide docking procedure in reproducing the
experimentally observed binding mode for NS5B
inhibitors. Therefore, the parameters set for Glide docking
appear reasonable to provide meaningful insight into the
predicted binding mode for coumestans.
Employing Glide molecular docking, we investigated
the interactions of the coumestan analogues at the HCV
NS5B NNI binding site and analysed the relationship
between their calculated binding energies (Gscore) and
IC50 values. As seen in Table 1, docking of coumestans
into NS5B NNI binding site for tetracyclic indole
(allosteric pocket 1) yielded an excellent correlation
between their Gscores and IC50 values. LQB34, the best
inhibitor of this series exhibited the most negative Gscore
in comparison to the other analogues, indicating a better
ﬁt at the binding site, whereas LQB16, the least potent
coumestan displayed the least negative Gscore, with other
analogues displaying binding scores consistent with their
IC50 values. A somewhat similar trend of overall agree-
ment between the binding energies and IC50 values was
also observed upon docking the coumestans at the NS5B
NNI binding site for N,N-disubstituted phenylalanine
(allosteric pocket 2), with the exception that LQB93 and
LQB96 which exhibited a three-fold diﬀerence in their
IC50 values showed near similar Gscores. Further
comparison revealed that the coumestans exhibited a
better ﬁt in allosteric pocket 1 versus allosteric pocket 2, as
deduced from the relatively more negative Gscores in the
former pocket. In contrast, binding of coumestans into the
NS5B benzothiadiazine-binding site (allosteric pocket 3)
located adjacent to the active site was ruled out based on
the poor Gscore values derived from the scoring function
at this site (data not shown). Together this analysis
suggests that allosteric pocket 1, represented by the NS5B
NNI binding site for tetracyclic indole may be the
potential site of coumestan binding.
To gain insight into the mechanism of inhibition by the
coumestans, we analysed the interactions of the docked
conformation of LQB34 within allosteric pocket 1
(Figure 8A and 8B). The benzofuran moiety of LQB34
was located in a deep hydrophobic pocket formed by
residues Leu392, Ala395, Ala396, Ile424, Leu425 and
His428 whereas its coumarin moiety interacts with Val494,
Pro495 and Trp500 and was fairly solvent-exposed.
Further, LQB34 was engaged in a series of electrostatic
interactions across the entire shallow-binding pocket of
NS5B. Notably, its 8-OH group forms hydrogen bond
with the backbone of Leu392 whereas its 9-OH group was
located at hydrogen bonding distances (3.37A ˚ ) from the
backbone of Ile424. Its benzofuran ring oxygen exhibited
electrostatic contact with the His428 ring –NH function
whereas the oxygen atom of its 2-OCH3 group was closely
located (2.34A ˚ ) to the guanidine function of Arg503 and
Figure 8. (A) Docked conformation of the most potent compound
LQB34 in the HCV NS5B NNI binding site for tetracyclic indole
(PDB ID: 2DXS) (54). Hydrogen bonds are shown as dotted yellow
lines. Distances are shown as dotted pink lines. Active site amino acid
residues are represented as sticks while the inhibitor is shown as ball
and stick model. (B) Docked (ball and stick model) conformation of
LQB34 overlaid within the Macromodel surface of the allosteric-
binding site of NS5B. (C) Hydrophilic (green color) and hydrophobic
(white color) surface area of the allosteric-binding site of NS5B (PDB
ID: 2DXS) in the presence of the most potent compound LQB34.
1492 Nucleic Acids Research, 2008, Vol. 36, No. 5possibly interacts through hydrogen bond. The predicted
binding mode agrees well with the observed SAR. For
instance, conversion of the 8-OH into 8-OCH3 group
results in the loss of hydrogen bond interaction between
the backbone of Leu392 of NS5B and the inhibitor, in
addition to causing steric hindrance with the side chain of
Ala395. This may account for the dramatically reduced
inhibitory potency of LQB16 and LQB93 (Table 1).
Removal of this steric hindrance by modiﬁcation of 8- and
9-OH function into a methylenedioxy derivative such as in
LQB96 reasonably improved the potency of the inhibitor.
Thus, the predicted pose of LQB34 suggests that extension
of the 8- and 9-OH function may be detrimental to the
potency of the inhibitor.
DISCUSSION
Identiﬁcation and characterization of several structural
classes of NNIs of NS5B has previously been reported.
In this study, we have identiﬁed the coumestan family
of isoﬂavones as novel inhibitors of HCV NS5B
RdRp activity in vitro. Coumestans occur naturally in a
balanced diet, are readily bioavailable, and are not
associated with any type of toxicity (64,65), thus making
them potentially attractive candidates for development as
clinically relevant agents.
The basic structure of the coumestan scaﬀold including
its coumarin moiety can be modiﬁed chemically to
enhance SAR, an aspect corroborated in the present
investigation where LQB34 was the most potent ( 2t o
20-fold lower IC50 value) of the ﬁve coumestans tested.
The variable potency of these compounds may be
attributed to the diﬀerent pattern of oxygenation on
their A- and D-ring structures as is substantiated by our
data, wherein LQB16 carrying methoxy groups on both
rings A and D exhibited reduced anti-NS5B activity
in contrast to wedelolactone and LQB34, the two
most potent coumestans of this group, both of which
harbored hydroxyl and catechol groups on their rings
A and D, respectively. Not surprisingly, the anti-NS5B
eﬃcacy of these compounds inversely correlated with
their hydrophobicity, thus providing an important
physicochemical parameter to be considered for future
optimization of coumestan structures.
A number of basic similarities were revealed in the
mechanism of inhibition of coumestans with other
characterized NNIs of HCV polymerase. Kinetic
experiments yielded a noncompetitive mode of inhibition
of the coumestan analogues towards nucleotide sub-
strates, akin to representative compounds of the six
chemically distinct scaﬀolds of NNIs (i) benzothiadiazine
(31,60), (ii) benzylidene (49,66), (iii) benzimidazole
(50,67), (iv) N,N-disubstituted phenylalanine (33),
(v) dihydropyranone (68) and (vi) pyrano indole (69),
all of which are noncompetitive inhibitors of NTP incor-
poration and reported to bind directly to NS5B poly-
merase. In the present study, we have no direct evidence
linking coumestan binding to NS5B. However, the
somewhat increased potency of these compounds upon
pre-incubation with NS5B, in addition to the observation
that the resolved NS5B-inhibitor complex demonstrated
reduced RdRp activity, argues in favor of direct coume-
stan binding to NS5B.
In the modiﬁed order of addition experiments, the
coumestans, like the benzylidenes (49) but contrary to the
benzothiadiazines (70), exhibited decreased eﬃcacy under
conditions of NS5B-RNA pre-incubation. Hence, access
to the coumestan-binding site may be partially occluded
either directly by the presence of nucleic acid, or by con-
formational changes that follow RNA binding. Evidence
for RNA-mediated protection of NS5B inactivation is also
indicated by the steady state kinetic data wherein these
analogues exhibited a mixed mode of inhibition towards
the template/primer with a signiﬁcant competitive com-
ponent similar to that reported for the benzimidiazoles
(52). We believe that the coumestans, similar to the
benzylidene and benzimidazole series, inhibit NS5B at an
early step during initiation of RNA synthesis, possibly
concurrent with NS5B-RNA complex formation step.
This speculation is consistent with our observation that no
abortive or prematurely terminated products were
observed in the primer-elongation reactions containing
the coumestans. Given that NS5B like other polymerases
follows an ordered mechanism of RNA synthesis, wherein
nucleic acid substrate must ﬁrst bind, followed by
nucleotide substrate in order to form a productive
polymerase complex, evidence that the two most active
compounds, wedelolactone and LQB34, compete with the
RNA/RNA TP in the cross-linking experiments, is
certainly indicative of inhibition of the formation of a
prepolymerase complex. Importantly, the decrease in
formation of binary complex correlates well with the
inhibition of polymerization activity, suggesting that these
compounds inhibit NS5B by binding mostly the free
enzyme rather than a preformed E-RNA/RNA complex.
Hence, the coumestans are likely to bind at an allosteric
site and decrease binding of RNA through an allosteric
mechanism.
Crystallographic studies on NS5B in complex with
allosteric inhibitors have suggested the presence of a
relatively shallow-binding site (59). A shallow-binding
pocket facilitates access to the binding partner (in our
case coumestans) and enhances the on-rate. However, a
shallow interface will also increase access of free water
molecules, which would undermine the stability of
the partnering complex unless the complex is stabilized
by other means. In order to design tight-binding inhibitors
for this site of NS5B, it is crucial to evaluate the
advantages and disadvantages of the shallow pocket.
For example, NS5B allosteric-binding site is predomi-
nantly solvent-exposed, thus for an inhibitor to approach
and bind to this site requires signiﬁcant displacement
of solvent molecules while the inhibitor itself can
simultaneously undergo predominant desolvation upon
moving from bulk to the shallow-binding pocket. In case
of coumestans, the coumarin moiety at the binding site
remains solvent-exposed thereby reducing desolvation
penalty to a minimum. Displacement of water molecules
from the binding site usually leads to increase in entropy,
Nucleic Acids Research, 2008, Vol. 36, No. 5 1493provided lost protein-water contacts are reestablished by
the inhibitor. We propose that the two hydroxyl groups
present in the D-ring form hydrogen bonding network
with the binding site residues. Such interactions can
compensate for the lost water-protein interactions. Our
docking results have shown that free coumestans do not
undergo conformational change upon binding to NS5B
due to the lack of rotatable bonds (except –OCH3 groups)
and therefore do not loose entropy thereby reﬂecting a
strong correlation between their inhibitory activities and
calculated binding energies (Gscore).
Considering protein ﬂexibility in solution, the behavior
of the predicted complex of the most potent inhibitor
LQB34 was studied in a dynamic context. MD simulations
yielded a stable complex reinforcing the validity of the
Gscore. The superposition of the coordinates of an
energy-minimized average structure obtained from the
last 250 trajectories, onto the starting complex yielded
r.m.s.d values of 1.430 and 1.210A ˚ for all atom-based and
ligand atom-based superposition, respectively. The r.m.s.d
value of 1.430A ˚ for all atoms of the NS5B-LBQ34
complex suggests that NS5B undergo conformational
changes which might aﬀect the RNA binding to the
enzyme upon coumestan binding. The stability of
the hydrogen bonding network predicted by Glide XP
docking method was examined by monitoring the
percentage occurrence of predicted hydrogen bonds
during simulation time. Analysis of the MD trajectory
suggested the occurrence of Glide-predicted hydrogen
bond in 85% of the complexes. The new hydrogen bond
(9-OH----O Ile424) was predicted in 27% of the
complexes. A detailed investigation on the binding
modes of coumestan inhibitors to NS5B followed by
MD simulations is likely to provide useful guideline to
design future inhibitors with enhanced activity.
The binding mode of LQB34 suggests ways to further
improve upon potency of coumestan derivatives.
For example, the C-7 position of the benzofuran moiety
can be substituted to ﬁt the narrower hydrophobic pocket
formed by Val37, Leu392, Ala393, Leu492 and Val494
(Figure 8B). Structural studies have shown that Arg503
stabilizes the NS5B NNI such as benzimidazole/
indole-based inhibitors (59). Hence, a –COOH modiﬁca-
tion of the C-2 methoxy group located in proximity of
Arg503 would allow a favorable charge–charge interaction
for binding. In addition, the 3-hydroxy group of LQB34,
which is not in direct contact with NS5B, can be
modiﬁed to attain desired pharmacokinetic proﬁle.
Also, modiﬁcation of coumestans’ benzofuran and/or
coumarin core structure and peripheral hydroxyl and/or
methoxy groups to better accommodate the hydrophobic/
hydrophilic surface map of NS5B binding pocket
(Figure 8C) may prove instrumental for further SAR
studies on coumestan derivatives.
In conclusion, we have identiﬁed and described the
mechanism of inhibition of a new series of NNIs
belonging to the coumestan family. Coumestans represent
novel structural templates of anti-NS5B inhibitors which
can be further modiﬁed into very potent drugs against
HCV through the application of molecular modeling and
SAR analyses. Studies are underway to develop and screen
other coumestan derivatives and evaluate their eﬃcacy in
HCV replicon system.
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